AriBio Co., Ltd.: First Participants Enrolled in the AriBio USA Phase 3 Registration Trial to Evaluate AR1001 in Early Alzheimer's Disease

AriBio USA, a clinical-stage biopharmaceutical company, announced the enrollment of their first participants in their Phase 3 trial to evaluate the efficacy of AR1001 in participants with early Alzheimer's

Related Keywords

San Diego ,California ,United States ,South Korea ,Matthew Choung ,Kostenloser Wertpapierhandel ,Fred Kim ,Aribio Ltd ,Aribio Co Ltd ,Aribio United States Inc ,Aribio United States ,Clinical Dementia Rating Scale Sum ,Aribio United ,Bio United States ,James Rock ,Fbio Ltd ,Multi Center Trial ,Early Alzheimer ,Aribio ,First ,Participants ,Unrolled ,Hase ,Registration ,Trial ,Valuate ,Hr1001 ,Early ,Lzheimer ,Disease ,